Other

Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

Chugai Seiyaku Kabushiki Kaisha

Nitto-Denko Corporation

Osaka University

Cosmed Pharmaceutical Co., Ltd.

Public University Corporation Nara Medical University

Nakagawa, Shinsaku

Tsutsumi, Yasuo

Mayumi, Tadanori

National Institute of Biomedical Innovation, Healty and Nutrition

Shinsaku Nakagawa

Tadanori Mayumi

Yasuo Tsutsumi

Tsunetaka Ohta

Iwao Ohizumi

Masashi Kurimoto

Kakuji Torigoe

Kiichi Fukui

Madoka Taniai

Mahito Nakanishi

Hakuo Ikegami

Ying-Shu Quan

Hideo Asada

Naoki Okada

Sachiko Hirobe

The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.

Human tumor necrosis factor-&#x3b1; mutants

Tumor necrosis factor-alpha mutants

The number of peptides having an ability to bind to a cell or penetrate into a cell is narrowed down by being selectively enriched from a random peptide library with a diversity of not less than one hundred millions of peptides using a phage surface display technique, and then cytoplasmic transfer is evaluated by using protein synthesis inhibition as an indicator by adding to a cell, a fusion body of the selectively enriched peptide and a protein synthesis inhibitory factor (PSIF) that cannot solely penetrate into the cell.

Cell permeable peptide

The present invention has objects to provide a mutant interferon-&#x3b1; protein having a higher anti-viral and anti-tumor activity and to provide an agent for susceptive diseases, which contains the mutant interferon-&#x3b1; protein as an effective ingredient; and solves the above objects by providing a mutant protein which has an amino acid sequence of human interferon-&#x3b1; subtype &#x3b1;8 represented by any one of SEQ ID NOs:1 to 3, where the arginine residue at the 145has been replaced with leucine, isoleucine, or valine residue; the alanine residue at the 146has been replaced with asparagine or serine residue; and the methionine residue at the 149has been replaced with tyrosine residue; and an agent for susceptive diseases, containing the mutant protein.

Mutant interferon &#x3b1; protein and use thereof

A monoclonal antibody which recognizes an antigen of a molecular weight of 40 kD or 80 kD on the surface of tumor vessel endothelial cells, hybridomas producing the monoclonal antibody, pharmaceutical agents comprising the monoclonal antibody, as well as pharmaceutical or diagnostic agents comprising a conjugate of the monoclonal antibody and another conjugating molecule.

Tumor vessel endothelial cell-binding monoclonal antibodies

Disclosed is a physiologically active complex which comprises a proteinaceous part with TNF activity and a high molecular part bound artificially to the N-terminus of the proteinaceous part. The proteinaceous part in the complex has the amino acid sequence of SEQ ID NO:2 where Xaa is a member selected from the group consisting of asparagine, alanine, arginine, serine, threonine, proline, methionine, and leucine; while the high molecular part in the complex is a homopolymer of polyethylene glycol, copolymer of polyethylene glycol, or a derivative thereof.

Physiologically active complex

A substance of interest is contained in nanospheres which are then encapsulated in fusogenic liposomes to prepare transport carriers that allow physiologically active substances, especially those having high molecular weight such as proteins and genes, to be introduced into cells efficiently and which permit the introduced active substance to be released in the cell at controlled rate. The fusogenic liposomes are prepared by conferring the fusogenic capability of Sendai virus to known liposomes.

Method of intracellular sustained-release of drug and preparations

A monoclonal antibody which recognizes an antigen of a molecular weight of 40 kD or 80 kD on the surface of tumor vessel endothelial cells, hybridomas producing said monoclonal antibody, pharmaceutical agents comprising said monoclonal antibody, as well as pharmaceutical or diagnostic agents comprising a conjugate of said monoclonal antibody and another conjugating molecule.

Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel

Growing community of inventors

Osaka, Japan

Shinsaku Nakagawa